Drugs to treat various diseases and cardiovascular risk factors such as obesity, hypertension, diabetes and high cholesterol, which together are known as the Metabolic Syndrome.
Currently, there is no drug to treat metabolic syndrome as a whole, but only specific treatments for its components in isolation. Thus, an inhibitor of the 11β-HSD1 enzyme could provide simultaneous treatment for these diseases, improving adherence and specificity of the therapy.
By using structural bioinformatics tools and biological evaluation techniques in metabolically relevant cell lines to identify and optimize new drugs aimed at selectively inhibiting the activity of the 11β-HSD1 enzyme.
Physician-Surgeon at the University of Chile, specializing in Internal Medicine and Endocrinology at the Pontifical Catholic University of Chile, Post Doctorate in Molecular Biology from the University of California San Francisco (UCSF). World expert on the subject of Mineralocorticoid Hypertension for the Endocrine Society.READ MORE
This would reduce combination therapy, side effects and associated costs. At a national level we have calculated the recovery of years of healthy life (AVISA) lost by the population, due to disability and premature death due to metabolic syndrome. Conceptually the benefit comes from the recovery of AVISA by having a drug that allows the simultaneous treatment of hypertension and diabetes.